SB 570: Prenatal screening program.
- Session Year: 2023-2024
- House: Senate
- Latest Version Date: 2023-07-13
Current Status:
Failed
(2023-09-01: September 1 hearing: Held in committee and under submission.)
Introduced
In Committee
First Chamber
In Committee
Second Chamber
Enacted
Existing law requires the State Department of Public Health to administer a statewide program for prenatal testing for genetic disorders and birth defects, including, but not limited to, ultrasound, amniocentesis, chorionic villus sampling, and blood testing. Existing law requires the department to expand prenatal screening to include all tests that meet or exceed the current standard of care as recommended by nationally recognized medical or genetic organizations and to establish any rules, regulations, and standards for prenatal diagnostic testing and the allocation of subsidies, as specified.
Existing law requires a clinical laboratory performing laboratory tests or examinations classified as moderate or high complexity under the federal Clinical Laboratory Improvement Amendments of 1988 (CLIA) to obtain a clinical laboratory license from the department. Existing law generally exempts specified clinical laboratories from rules and regulations of the department, including clinical laboratories owned and operated by the United States and certified under CLIA. Under existing regulations, a certificate of accreditation issued by the United States Department of Health and Human Services is considered a state license or registration issued by the department, as specified. Existing law requires a city or county public health laboratory, as specified, to be approved by the department and to comply with the requirements of CLIA.
This bill would prohibit the department, by way of rule, regulation, contract, or any other manner, from preventing a laboratory with both a CLIA certificate of accreditation and a current state clinical or public health laboratory license from offering all noninvasive prenatal tests to pregnant persons who have an order from a prenatal care provider, as defined. The bill would also prohibit the department from limiting the number of noninvasive prenatal tests that the laboratory may provide.
Existing law requires the State Department of Public Health to administer a statewide program for prenatal testing for genetic disorders and birth defects, including, but not limited to, ultrasound, amniocentesis, chorionic villus sampling, and blood testing. Existing law requires the department to expand prenatal screening to include all tests that meet or exceed the current standard of care as recommended by nationally recognized medical or genetic organizations and to establish any rules, regulations, and standards for prenatal diagnostic testing and the allocation of subsidies, as specified.
Existing law requires a clinical laboratory performing laboratory tests or examinations classified as moderate or high complexity under the federal Clinical Laboratory Improvement Amendments of 1988 (CLIA) to obtain a clinical laboratory license from the department. Existing law generally exempts specified clinical laboratories from rules and regulations of the department, including clinical laboratories owned and operated by the United States and certified under CLIA. Under existing regulations, a certificate of accreditation issued by the United States Department of Health and Human Services is considered a state license or registration issued by the department, as specified. Existing law requires a city or county public health laboratory, as specified, to be approved by the department and to comply with the requirements of CLIA.
This bill would prohibit the department, by way of rule, regulation, contract, or any other manner, from interfering with a pregnant individuals ability to secure genetic screening testing as recommended or ordered by the pregnant individuals prenatal care provider, or both. preventing a laboratory with both a CLIA certificate of accreditation and a current state clinical or public health laboratory license from offering all noninvasive prenatal tests to pregnant persons who have an order from a prenatal care provider, as defined. The bill would also prohibit the department from limiting the number of noninvasive prenatal tests that the laboratory may provide.
Existing law requires the State Department of Public Health to administer a statewide program for prenatal testing for genetic disorders and birth defects, including, but not limited to, ultrasound, amniocentesis, chorionic villus sampling, and blood testing. Existing law requires the department to expand prenatal screening to include all tests that meet or exceed the current standard of care as recommended by nationally recognized medical or genetic organizations and to establish any rules, regulations, and standards for prenatal diagnostic testing and the allocation of subsidies, as specified.
This bill would prohibit the department, by way of rule, regulation, contract, or any other manner, from interfering with a pregnant individuals ability to secure genetic screening testing as recommended or ordered by the pregnant individuals prenatal care provider, or both.
The department shall:
(a)Establish criteria for eligibility for the prenatal testing program. Eligibility shall include a definition of conditions and circumstances that result in a high risk of a detectable genetic disorder or birth defect.
(b)(1)Develop an education program designed to educate physicians and surgeons and the public concerning the uses of prenatal testing and the availability of the program.
(2)(A)Include information regarding environmental health in the California Prenatal Screening Program patient educational information. This environmental health information shall include the following statement:
We encounter chemicals and other substances in everyday life that may affect your developing fetus. Fortunately, there are steps you can take to reduce your exposure to these potentially harmful substances at home, in the workplace, and in the environment. Many Californians are unaware that a number of everyday consumer products may pose potential harm. Prospective parents should talk to their doctor and are encouraged to read more about this topic to learn about simple actions to promote a healthy pregnancy.
(B)The department shall include in the patient educational information links to educational materials derived from peer-reviewed materials based on the best available evidence relating to environmental health and reproductive toxins.
(C)The department shall post the environmental health information described in subparagraphs (A) and (B) on its internet website.
(D)The department shall send a notice to all distributors of the patient educational information informing them of the change to that information. In the notice, the department shall encourage obstetrician-gynecologists and midwives to discuss environmental health with their patients and to direct their patients to the appropriate page or pages in the patient educational information to provide their patients with additional information.
(E)In order to minimize costs, the environmental health information described in this paragraph shall be included when the patient educational information is otherwise revised and reprinted.
(F)The department may modify the language in the patient educational information after consultation with medical and scientific experts in the field of environmental health and reproductive toxins.
(c)Ensure that genetic counseling be given in conjunction with prenatal testing at the approved prenatal diagnosis centers.
(d)Designate sufficient prenatal diagnosis centers to meet the need for these services. Prenatal diagnosis centers shall have equipment and staff trained and capable of providing genetic counseling and performing prenatal diagnostic procedures and tests, including the interpretation of the results of the procedures and tests.
(e)Administer a program of subsidy grants for approved nonprofit prenatal diagnosis centers. The subsidy grants shall be awarded based on the reported number of low-income women referred to the center, the number of prenatal diagnoses performed in the previous year at that center, and the estimated size of unmet need for prenatal diagnostic procedures and tests in its service area. This subsidy shall be in addition to fees collected under other state programs.
(f)Establish any rules, regulations, and standards for prenatal diagnostic testing and the allocation of subsidies as the director deems necessary to promote and protect the public health and safety and to implement the Hereditary Disorders Act (Section 27).
(g)(1)The department shall expand prenatal screening to include all tests that meet or exceed the current standard of care as recommended by nationally recognized medical or genetic organizations, including, but not limited to, inhibin.
(2)The prenatal screening fee increase for expanding prenatal screening to include those tests described in paragraph (1) is forty dollars ($40).
(3)The department shall report to the Legislature regarding the progress of the program with regard to implementing prenatal screening for those tests described in paragraph (1) on or before July 1, 2007. The report shall include the costs of screening, followup, and treatment as compared to costs and morbidity averted by this testing under the program.
(4)(A)The expenditure of funds from the Genetic Disease Testing Fund for the expansion of the Genetic Disease Branch Screening Information System to include the expansion of prenatal screenings, pursuant to paragraph (1), may be implemented through the amendment of the Genetic Disease Branch Screening Information System contracts, and shall not be subject to Chapter 2 (commencing with Section 10290) or Chapter 3 (commencing with Section 12100) of Part 2 of Division 2 of the Public Contract Code, Article 4 (commencing with Section 19130) of Chapter 5 of Part 2 of Division 5 of Title 2 of the Government Code, or Sections 4800 to 5180, inclusive, of the State Administrative Manual as they relate to approval of information technology projects or approval of increases in the duration or costs of information technology projects. This paragraph shall apply to the design, development, and implementation of the expansion, and to the maintenance and operation of the Genetic Disease Branch Screening Information System, including change requests, once the expansion is implemented.
(B)(i)The department may adopt emergency regulations to implement and make specific the amendments to this section made during the 2006 portion of the 200506 Regular Session in accordance with Chapter 3.5 (commencing with Section 11340) of Part 1 of Division 3 of Title 2 of the Government Code. For the purposes of the Administrative Procedure Act, the adoption of regulations shall be deemed an emergency and necessary for the immediate preservation of the public peace, health and safety, or general welfare. Notwithstanding Chapter 3.5 (commencing with Section 11340) of Part 1 of Division 3 of Title 2 of the Government Code, these emergency regulations shall not be subject to the review and approval of the Office of Administrative Law. Notwithstanding Sections 11346.1 and 11349.6 of the Government Code, the department shall submit these regulations directly to the Secretary of State for filing. The regulations shall become effective immediately upon filing by the Secretary of State. Regulations shall be subject to public hearing within 120 days of filing with the Secretary of State and shall comply with Sections 11346.8 and 11346.9 of the Government Code or shall be repealed.
(ii)The Office of Administrative Law shall provide for the printing and publication of these regulations in the California Code of Regulations. Notwithstanding Chapter 3.5 (commencing with Section 11340) of Part 1 of Division 3 of Title 2 of the Government Code, the regulations adopted pursuant to this chapter shall not be repealed by the Office of Administrative Law and shall remain in effect until revised or repealed by the department.
(h)(1)The department shall not, by way of a rule, regulation, contract, or any other manner, prohibit a laboratory that has both a current Clinical Laboratory Improvement Amendments certificate of accreditation and a current state clinical or public health laboratory license from offering all noninvasive prenatal tests, as ordered by a prenatal care provider, or otherwise limit the number of tests that the laboratory may provide, including, but not limited to, testing for autosomal trisomies (trisomies 21, 18, and 13), microdeletions, and fetal sex, to a pregnant person who has an order from a prenatal care provider.
(2)As used in this section, prenatal care provider means a health care provider licensed pursuant to Division 2 (commencing with Section 500) of the Business and Professions Code, or pursuant to an initiative act referred to in that division, who provides prenatal medical care within their scope of practice. This definition shall not include a licensed health care professional who provides care other than prenatal care to a pregnant patient.
The department shall:
(a)Establish criteria for eligibility for the prenatal testing program. Eligibility shall include definition of conditions and circumstances that result in a high risk of a detectable genetic disorder or birth defect.
(b)(1)Develop an education program designed to educate physicians and surgeons and the public concerning the uses of prenatal testing and the availability of the program.
(2)(A)Include information regarding environmental health in the California Prenatal Screening Program patient educational information. This environmental health information shall include the following statement:
We encounter chemicals and other substances in everyday life that may affect your developing fetus. Fortunately, there are steps you can take to reduce your exposure to these potentially harmful substances at home, in the workplace, and in the environment. Many Californians are unaware that a number of everyday consumer products may pose potential harm. Prospective parents should talk to their doctor and are encouraged to read more about this topic to learn about simple actions to promote a healthy pregnancy.
(B)The department shall include in the patient educational information links to educational materials derived from peer-reviewed materials based on the best available evidence relating to environmental health and reproductive toxins.
(C)The department shall post the environmental health information described in subparagraphs (A) and (B) on its Internet Web site. internet website.
(D)The department shall send a notice to all distributors of the patient educational information informing them of the change to that information. In the notice, the department shall encourage obstetrician-gynecologists and midwives to discuss environmental health with their patients and to direct their patients to the appropriate page or pages in the patient educational information to provide their patients with additional information.
(E)In order to minimize costs, the environmental health information described in this paragraph shall be included when the patient educational information is otherwise revised and reprinted.
(F)The department may modify the language in the patient educational information after consultation with medical and scientific experts in the field of environmental health and reproductive toxins.
(c)Ensure that genetic counseling be given in conjunction with prenatal testing at the approved prenatal diagnosis centers.
(d)Designate sufficient prenatal diagnosis centers to meet the need for these services. Prenatal diagnosis centers shall have equipment and staff trained and capable of providing genetic counseling and performing prenatal diagnostic procedures and tests, including the interpretation of the results of the procedures and tests.
(e)Administer a program of subsidy grants for approved nonprofit prenatal diagnosis centers. The subsidy grants shall be awarded based on the reported number of low-income women referred to the center, the number of prenatal diagnoses performed in the previous year at that center, and the estimated size of unmet need for prenatal diagnostic procedures and tests in its service area. This subsidy shall be in addition to fees collected under other state programs.
(f)Establish any rules, regulations, and standards for prenatal diagnostic testing and the allocation of subsidies as the director deems necessary to promote and protect the public health and safety and to implement the Hereditary Disorders Act (Section 27).
(g)(1)The department shall expand prenatal screening to include all tests that meet or exceed the current standard of care as recommended by nationally recognized medical or genetic organizations, including, but not limited to, inhibin.
(2)The prenatal screening fee increase for expanding prenatal screening to include those tests described in paragraph (1) is forty dollars ($40).
(3)The department shall report to the Legislature regarding the progress of the program with regard to implementing prenatal screening for those tests described in paragraph (1) on or before July 1, 2007. The report shall include the costs of screening, followup, and treatment as compared to costs and morbidity averted by this testing under the program.
(4)(A)The expenditure of funds from the Genetic Disease Testing Fund for the expansion of the Genetic Disease Branch Screening Information System to include the expansion of prenatal screenings, pursuant to paragraph (1), may be implemented through the amendment of the Genetic Disease Branch Screening Information System contracts, and shall not be subject to Chapter 2 (commencing with Section 10290) or Chapter 3 (commencing with Section 12100) of Part 2 of Division 2 of the Public Contract Code, Article 4 (commencing with Section 19130) of Chapter 5 of Part 2 of Division 5 of Title 2 of the Government Code, or Sections 4800 to 5180, inclusive, of the State Administrative Manual as they relate to approval of information technology projects or approval of increases in the duration or costs of information technology projects. This paragraph shall apply to the design, development, and implementation of the expansion, and to the maintenance and operation of the Genetic Disease Branch Screening Information System, including change requests, once the expansion is implemented.
(B)(i)The department may adopt emergency regulations to implement and make specific the amendments to this section made during the 2006 portion of the 200506 Regular Session in accordance with Chapter 3.5 (commencing with Section 11340) of Part 1 of Division 3 of Title 2 of the Government Code. For the purposes of the Administrative Procedure Act, the adoption of regulations shall be deemed an emergency and necessary for the immediate preservation of the public peace, health and safety, or general welfare. Notwithstanding Chapter 3.5 (commencing with Section 11340) of Part 1 of Division 3 of Title 2 of the Government Code, these emergency regulations shall not be subject to the review and approval of the Office of Administrative Law. Notwithstanding Sections 11346.1 and 11349.6 of the Government Code, the department shall submit these regulations directly to the Secretary of State for filing. The regulations shall become effective immediately upon filing by the Secretary of State. Regulations shall be subject to public hearing within 120 days of filing with the Secretary of State and shall comply with Sections 11346.8 and 11346.9 of the Government Code or shall be repealed.
(ii)The Office of Administrative Law shall provide for the printing and publication of these regulations in the California Code of Regulations. Notwithstanding Chapter 3.5 (commencing with Section 11340) of Part 1 of Division 3 of Title 2 of the Government Code, the regulations adopted pursuant to this chapter shall not be repealed by the Office of Administrative Law and shall remain in effect until revised or repealed by the department.
(h)(1)The department shall not, by way of a rule, regulation, contract, or any other manner, prohibit a laboratory that has both a current Clinical Laboratory Improvement Amendments certificate of accreditation and a current state clinical or public health laboratory license from offering all noninvasive prenatal tests, as ordered by a prenatal care provider, or otherwise limit the number of tests that the laboratory may provide, including, but not limited to, testing for autosomal trisomies (trisomies 21, 18, and 13), microdeletions, and fetal sex, to a pregnant person who has an order from a prenatal care provider.
(2)As used in this section, prenatal care provider means a health care provider licensed pursuant to Division 2 (commencing with Section 500) of the Business and Professions Code, or pursuant to an initiative act referred to in that division, who provides prenatal medical care within their scope of practice. This definition shall not include a licensed health care professional who provides care other than prenatal care to a pregnant patient.
SECTION 1.Section 125055.1 is added to the Health and Safety Code, to read:125055.1.The department shall not, by way of rule, regulation, contract, or any other manner, interfere with a pregnant individuals ability to secure genetic screening testing as recommended or ordered by the pregnant individuals prenatal care provider, or both.The department shall not, by way of rule, regulation, contract, or any other manner, interfere with a pregnant individuals ability to secure genetic screening testing as recommended or ordered by the pregnant individuals prenatal care provider, or both.
|
Date
|
Status
|
|---|---|
| Sep 1, 2023 | September 1 hearing: Held in committee and under submission. |
| Aug 23, 2023 | August 23 set for first hearing. Placed on suspense file. |
| Aug 16, 2023 | August 16 hearing postponed by committee. |
| Jul 13, 2023 | Read second time and amended. Re-referred to Com. on APPR. |
| Jul 12, 2023 | From committee: Do pass as amended and re-refer to Com. on APPR. (Ayes 13. Noes 0.) (July 11). |
| Jun 8, 2023 | Referred to Com. on HEALTH. |
| May 25, 2023 | In Assembly. Read first time. Held at Desk. |
| May 25, 2023 | Read third time. Passed. (Ayes 40. Noes 0. Page 1302.) Ordered to the Assembly. |
| May 23, 2023 | Ordered to special consent calendar. |
| May 18, 2023 | Read second time. Ordered to third reading. |
| May 18, 2023 | From committee: Do pass. (Ayes 7. Noes 0. Page 1175.) (May 18). |
| May 12, 2023 | Set for hearing May 18. |
| Apr 17, 2023 | April 17 hearing: Placed on APPR suspense file. |
| Apr 11, 2023 | Set for hearing April 17. |
| Apr 10, 2023 | Read second time and amended. Re-referred to Com. on APPR. |
| Mar 30, 2023 | From committee: Do pass as amended and re-refer to Com. on APPR. (Ayes 12. Noes 0. Page 575.) (March 29). |
| Mar 16, 2023 | Set for hearing March 29. |
| Feb 22, 2023 | Referred to Com. on HEALTH. |
| Feb 16, 2023 | From printer. May be acted upon on or after March 18. |
| Feb 15, 2023 | Introduced. Read first time. To Com. on RLS. for assignment. To print. |
|
Date
|
Description
|
Location
|
Votes
|
|
|---|---|---|---|---|
| Jul 11, 2023 | Do pass as amended and be re-referred to the Committee on [Appropriations] | Assembly Standing Committee on Health |
Passed |
|
| May 25, 2023 | Special Consent SB570 Becker et al. | Senate Floor |
Passed |
|
| May 18, 2023 | Do pass | Senate Standing Committee on Appropriations |
Passed |
|
| Apr 17, 2023 | Placed on suspense file | Senate Standing Committee on Appropriations |
Passed |
|
| Mar 29, 2023 | Do pass as amended, but first amend, and re-refer to the Committee on [Appropriations] | Senate Standing Committee on Health |
Passed |
This list shows positions taken on this bill by organizations on the date displayed, which is linked to the original source.
Positions by individuals are not included.
|
Organization
|
Position
|
Date
|
|---|---|---|
| American College Of Obstetricians And Gynecologists District Ix | ** Support | |
| BillionToOne | ** Support | |
| BillionToOne, | ** Support | |
| California Academy Of Family Physicians | ** Support | |
| California Black Health Network | ** Support | |
| California Clinical Laboratory Association | ** Support | |
| California Life Sciences | ** Support | |
| California Nurse Midwives Association | ** Support | |
| Illumina, Inc. | ** Support | |
| Myriad Genetics Inc. | ** Support | |
| Natera, Inc. | ** Support | |
| Planned Parenthood Affiliates Of California | ** Support |
Date of Hearing: August 23, 2023
ASSEMBLY COMMITTEE ON APPROPRIATIONS
Chris Holden, Chair
SBPCA Bill Id:SB 570
Author:(Becker) – As Amended Ver:July 13, 2023
Policy Committee: | Health | Vote: | 13 - 0 |
|
| ||
|
|
Urgency: No State Mandated Local Program: No Reimbursable: No
SUMMARY:
This bill prohibits the California Department of Public Health (CDPH) from prohibiting, in any manner, a clinical laboratory from offering all noninvasive prenatal tests (NIPTs) ordered by a prenatal care provider, or otherwise limiting the number of tests that the laboratory may provide, to a pregnant person who has an order from a prenatal care provider.
FISCAL EFFECT:
Cost pressures of an unknown amount, possibly in the millions of dollars annually, to the Medi-Cal program to the extent prenatal care providers are more likely to recommend pregnant Medi-Cal enrollees choose prenatal testing outside of CDPH’s Prenatal Screening (PNS) program as a result of this bill. According to CDPH, Medi-Cal reimburses $607 per specimen for a NIPT using cell-free DNA (cfDNA), and $1,500 for follow-up tests when indicated by the screening provided by laboratories outside the PNS program. Approximately 2% of those screened are referred for follow-up testing.
Screening in the PNS Program costs $232 per participant; this price includes follow-up testing when indicated. If a Medi-Cal patient receives prenatal testing through the PNS program, Medi-Cal will cover the cost at the lower PNS rate. CDPH reports approximately 300,000 people participate in the PNS program each year. Medi-Cal covers more than half of California births. If 1,000 Medi-Cal enrollees choose to get NIPT screening outside of the PNS, and 2% require follow-up testing, the Medi-Cal program would need to pay $637,000, which is $405,000 more than if those enrollees instead obtained their screening through the PNS Program (General Fund, federal funds).
COMMENTS:
- Purpose. According to the author:
SB 570 seeks to restore a pregnant individual’s decision to utilize all available prenatal services to make informed decisions about their and their newborn’s healthcare. Pregnant individuals and their physicians commonly seek screening for a variety of sex chromosomes anomalies that can have significant impacts on the pregnancy and the newborn. Known as Non-Invasive Prenatal Testing (NIPT), this prenatal cell-free DNA screening is the primary prenatal screening for these anomalies. In late 2022, however, the California Department of Health (DPH) implemented major changes to the Prenatal Screening (PNS) Program, which impede access to certain services that pregnant individuals previously enjoyed. These changes limit the types of genetic screening pregnant individuals are able to receive through the PNS Program. SB 570 will once again allow pregnant individuals to access specific types of genetic screening – regardless of their PNS enrollment status – as recommended by their prenatal care provider.
- Background.
PNS Program. The PNS Program, administered by CDPH’s Genetic Disease Screening Program, provides prenatal screening services and follow-up diagnostic services, when indicated, to pregnant people in California, with the goal of detecting birth defects during pregnancy. The PNS Program offers screening tests for open neural tube defects, trisomy 21 (Down syndrome) and trisomies 13 and 18. When screening results indicate a high risk for a birth defect, the program provides follow-up diagnostic services at state-approved Prenatal Diagnosis Centers (PDCs). Services offered at PDCs include genetic counseling, ultrasound, and amniocentesis. Participation in the screening, testing, and follow-up services is voluntary and the fee is currently $232, which includes necessary follow-up testing.
NIPTs. NIPTs analyze small fragments of fetal deoxyribonucleic acid, or cell-free DNA (cfDNA), that are circulating in a pregnant person's blood. NIPTs are used to identify risk of certain genetic abnormalities. When used appropriately, these tests offer a non-invasive approach for prenatal screening and may provide useful information to assess the risk that a fetus has a genetic abnormality.
Transition to cfDNA Screening. In 2020, when the American College of Obstetricians and Gynecologists (ACOG) policy designated cfDNA screening for trisomies 21, 18 and 13 to be the standard of care, CDPH was statutorily required to implement the new standard of care as quickly as possible for the benefit of all pregnant people in California. In the 2021-22 state budget, the administration proposed, and the Legislature approved, a transition to cfDNA screening for trisomies 21, 18, and 13. According to CDPH, before it proposed making changes to the PNS Program, it conducted stakeholder meetings, the first of which occurred in 2019. Representatives from laboratories, ACOG, and others from the genetic counseling, prenatal, and bioethics community were invited and participated in a discussion about the PNS Program redesign. The PNS Program made cfDNA screening available to all pregnant individuals in California on September 19, 2022.
Lawsuits against CDPH. Three companies with laboratories that provide prenatal screening tests sued CDPH in two separate actions challenging CDPH’s newly adopted regulations pertaining to the state’s PNS program, alleging the regulations exceeded CDPH’s authority.
Under both cases, the superior court ruled in favor of the laboratories and issued an injunction prohibiting CDPH from enforcing the emergency regulations. Under the superior court’s order, any laboratory – including those without contracts with CDPH – may provide NIPT screening. The deadline to file an appeal was July 31, 2023.
Status of the PNS Program. According to CDPH’s PNS website, as a result of the court ruling, prenatal care providers may order prenatal screening tests outside of the PNS program from any licensed clinical laboratory. Prenatal care providers are still required to offer participation in the PNS program to their pregnant patients. Patients may choose not to participate in either type of testing offered through the PNS program. If they choose not to obtain screening through the PNS program, they may access screening outside of the PNS program through any licensed clinical laboratory. However, only patients who elect to participate in the PNS program will have access to follow-up genetic counseling and diagnostic services at one of the many state-contracted PDCs located throughout the state for any pregnancy determined to be high-risk, at no additional cost to the patient. PNS program participants with public or private insurance are not subject to out-of-pocket copays and/or deductibles. Prenatal care providers who order prenatal screening outside of the PNS program will need to arrange for follow-up counseling and diagnostic testing for their patients outside of the state program if follow-up is necessary.
In response to recently published recommendations from the American College of Medical Genetics and Genomics, CDPH plans to add screening for sex chromosome aneuploidies to the PNS program in 2024.
Analysis Prepared by: Allegra Kim / APPR. / (916) 319-2081
Date of Hearing: July 11, 2023
ASSEMBLY COMMITTEE ON HEALTH
Jim Wood, Chair
SBPCA Bill Id:SB 570
Author:(Becker) – As Amended Ver:April 10, 2023
SENATE VOTE: 40-0
SUBJECT: Prenatal screening program.
SUMMARY: Prohibits the Department of Public Health (DPH), by way of a rule, regulation, contract, or any other manner, from prohibiting a laboratory that has both a current Clinical Laboratory Improvement Amendments (CLIA) certificate of accreditation and a current state clinical or public health laboratory license from offering all noninvasive prenatal tests (NIPTs), as ordered by a prenatal care provider, or otherwise limiting the number of tests that the laboratory may provide, including, but not limited to, testing for autosomal trisomies (trisomies 21, 18, and 13), microdeletions (small missing piece of chromosome), and fetal sex, to a pregnant person who has an order from a prenatal care provider.
EXISTING LAW:
- Requires DPH to administer a statewide program for the prenatal testing for genetic disorders and birth defects, including, but not limited to, ultrasound, amniocentesis, chorionic villus sampling, and blood testing for genetic disorders and birth defects. [Health & Safety Code (HSC) §125050]
- Requires DPH to establish criteria for eligibility for the prenatal testing program, and requires eligibility to include a definition of conditions and circumstances that result in a high risk of a detectable genetic disorder or birth defect. Requires DPH to expand prenatal screening to include all tests that meet or exceed the current standard of care as recommended by nationally recognized medical or genetic organizations. [HSC §125055]
- Requires the participation by any individual in the prenatal testing program to be voluntary and not be a prerequisite to eligibility for, or receipt of, any other service or assistance from, or participation in, any other program. [HSC §125060]
FISCAL EFFECT: According to the Senate Appropriations Committee:
- Unknown cost pressures in the Medi-Cal program (General Fund and federal funds) to the extent that pregnant individuals enrolled in Medi-Cal would opt for prenatal testing outside of DPH’s Prenatal Screening (PNS) Program or choose to have tests in addition to the genetic tests offered as part of the PNS program. Currently, Medi-Cal payment rates to laboratories for prenatal testing are generally higher than PNS payment rates. If a Medi-Cal patient receives prenatal testing through the PNS program, Medi-Cal will cover the cost at the lower PNS rate.
- DPH anticipates decreased PNS program expenditures and revenues as pregnant individuals seek prenatal testing outside of the PNS program. However, DPH estimates that between $4.2 million to $17.5 million (Genetic Disease Testing Fund) in revenue loss would need to be offset by an increase in the fees charged for the PNS program, to cover fixed operational program costs.
COMMENTS:
- PURPOSE OF THIS BILL. According to the author, this bill seeks to restore a pregnant individual’s decision to utilize all available prenatal services to make informed decisions about their and their newborn’s healthcare. Pregnant individuals and their physicians commonly seek screening for a variety of sex chromosomes anomalies that can have significant impacts on the pregnancy and the newborn. NIPT is the primary prenatal screening for these anomalies. In late 2022, however, DPH implemented major changes to the PNS program, which impede access to certain services that pregnant individuals previously enjoyed. These changes limit the types of genetic screening pregnant individuals are able to receive through the PNS program. The author concludes this bill will once again allow pregnant individuals to access specific types of genetic screening, regardless of their PNS enrollment status, as recommended by their prenatal care provider.
- BACKGROUND. NIPTs analyze small fragments of fetal deoxyribonucleic acid, called cfDNA, that are circulating in a pregnant person's blood with the goal of determining the risk that the fetus has certain genetic abnormalities. When used appropriately, these tests offer a non-invasive approach for prenatal screening and may provide useful information to assess the risk that a fetus has (or does not have) a genetic abnormality. It should be noted that NIPTs are screening tests, not diagnostic tests. Screening tests generally predict a level of risk of the fetus having certain genetic abnormalities. Diagnostic tests, are generally used to more definitively confirm or rule out a suspected genetic abnormality.
- The PNS program. The PNS program, administered by DPH’s Genetic Disease Screening Program has been operational since 1986 and it provides prenatal screening services and follow-up diagnostic services, where indicated, to all pregnant persons in California to detect birth defects during pregnancy. The program offers three types of screening tests to pregnant individuals in order to identify individuals who are at increased risk for carrying a fetus with a specific birth defect:
- Sequential Integrated Screening – This screen combines first and second blood test results with nuchal translucency ultrasound results, which measure the back of a fetus' neck. This measurement helps screen for Down syndrome (trisomy 21).
- Serum Integrated Screening – This screen combines a first trimester blood test screening result with a second trimester blood test screening result.
- Quad Marker Screening - One blood specimen drawn at 15 weeks to 20 weeks of pregnancy (second trimester test).
- The PNS program. The PNS program, administered by DPH’s Genetic Disease Screening Program has been operational since 1986 and it provides prenatal screening services and follow-up diagnostic services, where indicated, to all pregnant persons in California to detect birth defects during pregnancy. The program offers three types of screening tests to pregnant individuals in order to identify individuals who are at increased risk for carrying a fetus with a specific birth defect:
The PNS program provides pregnant people with a risk assessment for open neural tube defects, Down syndrome, trisomy 18 and Smith-Lemli-Opitz Syndrome through one or two blood tests. The screening test indicates risk, but does not diagnose fetal birth defects. For people with screening results indicating a high risk for a birth defect, the PNS Program provides free follow-up diagnostic services at state-approved Prenatal Diagnosis Centers (PDCs). Services offered at PDCs include genetic counseling, ultrasound, and amniocentesis. Participation in the screening, testing and follow-up services is voluntary.
- Changes to the PNS Program. In the 2021-22 Budget, the Administration proposed and the Legislature approved a transition to cfDNA screening for trisomies 21, 18 and 13. Trisomy 21, or Down syndrome, is caused by an extra copy of chromosome 21. Trisomy 18, or Edwards syndrome, and trisomy 13, or Patau syndrome, are caused by an extra copy of chromosome 18 or 13, respectively; for both conditions, most babies born will have severe intellectual disability, and difficulty with growth and development. They usually have severe multiple birth defects and death during the first year of life. The two most common types of neural tube defects are spina bifida (an opening in the spine, which can cause paralysis and loss of bowel and bladder control) and anencephaly (a large part of the skull is missing and most of the brain does not develop).
According to DPH, before it proposed making changes to the PNS program, it conducted stakeholder meetings. The first cfDNA-related stakeholder meeting occurred in 2019. Representatives from laboratories, the American College of Obstetricians and Gynecologists (ACOG), and others from the genetic counseling, prenatal, and bioethics community were invited and participated in a discussion about the PNS program redesign. A detailed summary of this meeting was sent to all key stakeholders, including laboratories.
Once ACOG policy was released in 2020 indicating cfDNA screening for trisomies 21, 18 and 13 to be the standard of care, DPH was statutorily required to implement the new standard of care as quickly as possible for the benefit of all pregnant people in California (See Health & Safety Code Section 125055(g)(1)). DPH indicated it continued to consult with stakeholders since the 2019 meeting in the form of webinars for PNS providers, newsletters, announcements and invited input throughout the process. In 2019 and 2021, DPH surveyed cfDNA labs for input to the PNS program and DPH/PNS program staff have had a series of meetings with interested cfDNA labs since then. The general public is also invited to provide input as part of the regulatory process. - cfDNA. cfDNA screens for fetal chromosomal abnormalities through the extraction of fetal DNA that is contained in a maternal blood sample. Recent guidance from ACOG indicates cfDNA is the most sensitive and specific screening test for detecting common fetal aneuploidies. Fetal aneuploidies are conditions in which a fetus has one or more extra or missing chromosomes, such as trisomy 21 or trisomy 18. The American College of Medical Genetics and Genomics (ACMGG) indicates that cfDNA has been rapidly integrated into prenatal care and new evidence suggests it can replace conventional screening for chromosomal abnormalities. According to DPH, current screening for chromosomal abnormalities in the PNS program relies on analysis of maternal blood samples for levels of two to four pregnancy hormones. The results are used to calculate the risk for two chromosomal abnormalities and neural tube defects. This screening is only available during certain critical periods of pregnancy.
DPH points out that compared to the current PNS screening methodology, cfDNA has demonstrated superior performance and accuracy, may be performed at any time during a pregnancy, and provides more flexibility in the timing of testing for pregnant individuals. In addition, because cfDNA screening is diagnostic, rather than a risk-assessment, DPH expects adoption of cfDNA to reduce costs for public and private health care payers, as well as consumers with out-of-pocket costs, due to reduced need for follow-up screenings for chromosomal abnormalities, such as nuchal translucency examinations or amniocentesis. DPH estimates Medi-Cal would experience General Fund savings in the hundreds of thousands of dollars annually compared to current costs, beginning in 2022-23.
Using cfDNA as a primary screen provides the following benefits compared to biochemical screening:- cfDNA provides higher sensitivity and lower false-positive rates, resulting in fewer screen-positive cases referred for follow-up diagnostic services;
- The gestational age window will allow screening as early as 10 weeks of gestation; and,
- cfDNA can provide results for one additional aneuploidy (trisomy 13).
- Changes to the PNS Program. In the 2021-22 Budget, the Administration proposed and the Legislature approved a transition to cfDNA screening for trisomies 21, 18 and 13. Trisomy 21, or Down syndrome, is caused by an extra copy of chromosome 21. Trisomy 18, or Edwards syndrome, and trisomy 13, or Patau syndrome, are caused by an extra copy of chromosome 18 or 13, respectively; for both conditions, most babies born will have severe intellectual disability, and difficulty with growth and development. They usually have severe multiple birth defects and death during the first year of life. The two most common types of neural tube defects are spina bifida (an opening in the spine, which can cause paralysis and loss of bowel and bladder control) and anencephaly (a large part of the skull is missing and most of the brain does not develop).
DPH also points out that the PNS program, at this time, will not include screening for sex chromosome abnormalities or microdeletions. Providers can continue to order these screens, if they choose. However, the additional screens will require separate billing to the patient or their third-party payor and will not include follow-up services by the PNS program as they are not part of the approved PNS program.
As part of the implementation of cfDNA, DPH issued emergency regulations that were adopted on September 9, 2022. A provision on these regulations allow only laboratories contracted with DPH to perform prenatal screening for NTDs or perform cfDNA screening for trisomies 13, 18 and 21. DPH indicates that they currently have contracts with Quest Diagnostics, Natera, Perkin Elmer, and Kaiser Southern California for testing through the PNS program.
- Lawsuit against DPH brought by laboratories. According to the Attorney General’s Office, there are two separate (BillionToOne, Inc v. DPH; Laboratory Corporation of America Holdings v. DPH) but related actions brought by three companies with laboratories that provide prenatal screening tests challenging DPH’s newly adopted regulations pertaining to the state’s PNS program, alleging that the regulations exceed DPH’s authority.
Under both cases, the superior court ruled in favor of the laboratories and issued an injunction prohibiting DPH from enforcing the emergency regulations. Under the superior court’s order, any laboratory (including those without contracts with DPH or is not a provider or does not participate in the PNS program) can provide screening.
According to the AG, the deadline to file any appeal is July 31, 2023. - Current Status of PNS Program. According to DPH’s website, as a result of the court ruling, prenatal care providers may order prenatal screening tests outside of the PNS program from any licensed clinical laboratory. Prenatal care providers are still required to offer participation in the PNS program to their pregnant patients. Only patients who elect to participate in the PNS program will have access to free follow-up genetic counseling and diagnostic services at one of the many state-contracted PDCs located throughout the state for any pregnancy determined to be high-risk.
PNS program participants with public or private insurance will not be subject to out-of-pocket copays and/or deductibles. Prenatal care providers are still required to offer participation in the PNS program. Patients may choose not to participate in either type of testing offered through the PNS program. If they choose not to obtain screening through the PNS program, they may access screening outside of the PNS program through any licensed clinical laboratory.
Prenatal care providers who order prenatal screening outside of the PNS program will need to arrange for follow-up counseling and diagnostic testing for their patients outside of the state program if follow-up is necessary. Patients and their health insurance plans will likely be subject to higher prenatal screening and follow-up diagnostic fees compared with the PNS program.
The PNS program has not and does not prevent or limit providers from ordering screening tests not provided through PNS program, including screenings for sex chromosome abnormalities and other genetic conditions. Some of the current state-contracted screening laboratories allow the same blood draw used for the PNS program to be used for such additional screening, but providers must complete and submit a separate test requisition form.
In keeping with recent published recommendations from the ACMGG, DPH is currently planning to add screening for sex chromosome aneuploidies to the PNS program in 2024.” - Food and Drug Administration (FDA) Safety Communication. On April 19, 2022, the FDA issued a safety communication warning patients and health care providers about the risks of false results with NIPTs. The FDA points out that results from NIPTs can provide information about the possibility of a fetus having certain genetic abnormalities that could result in a child being born with a serious health condition.
While health care providers widely use NIPTs, none have yet been authorized, cleared, or approved by the FDA. The accuracy and performance of NIPTs have not been evaluated by the FDA and these tests can give false results, such as reporting a genetic abnormality when the fetus does not actually have one. NIPTs are screening tests, which means the NIPTs may only tell you the risk of the fetus having certain genetic abnormalities. They are not diagnostic tests, which are generally used to more definitively confirm or rule out a suspected genetic abnormality.
The FDA is aware of reports that patients and health care providers have made critical health care decisions based on results from these screening tests alone and without additional confirmatory testing. Specifically, pregnant people have ended pregnancies based only on the results of NIPTs. Without confirming the results with a diagnostic test, there is no way to know whether the fetus actually had the genetic abnormality reported by the screening test. The FDA is aware of cases where a screening test reported a genetic abnormality and a confirmatory diagnostic test later found that the fetus was healthy.
The FDA points out that any laboratories that offer these tests claim the tests are "reliable" and "highly accurate," offering "peace of mind" for patients. The FDA is concerned that these claims may not be supported with sound scientific evidence. False claims may cause patients as well as health care providers to believe the test results are reliable and can be used alone to make decisions about the pregnancy.- FDA recommendation. The FDA recommends that patients discuss the benefits and risks of NIPTs with a genetic counselor or other health care provider before deciding to get these tests. Patients should also discuss the results of NIPTs with a genetic counselor or other health care provider before making any decisions about their pregnancy. Health care providers should be aware of the risks and limitations of using these screening tests and should not use the results from these tests alone to diagnose chromosomal (genetic) abnormalities or disorders. The guidance points out that the ability of a NIPT to correctly tell whether a fetus is at risk for a genetic abnormality depends on how common or rare the genetic abnormality is and on underlying risk factors. Disorders caused by a microdeletion are rare. Because these conditions are so rare, a positive result may be more likely to be from a healthy fetus than one that actually has the reported genetic abnormality.
- Positions of Professional Societies. The safety communication also summarized the positions of relevant professional societies including ACOG, the Society for Maternal-Fetal Medicine, and ACMGG:
- Lawsuit against DPH brought by laboratories. According to the Attorney General’s Office, there are two separate (BillionToOne, Inc v. DPH; Laboratory Corporation of America Holdings v. DPH) but related actions brought by three companies with laboratories that provide prenatal screening tests challenging DPH’s newly adopted regulations pertaining to the state’s PNS program, alleging that the regulations exceed DPH’s authority.
- These medical professional societies recommend that prenatal genetic screening should be discussed and offered to all patients regardless of their age or risk for a chromosomal abnormality.
- Patient education is emphasized in order to support informed decision making about whether to accept or decline screening. Emphasis is placed on education surrounding the positive predictive value of NIPTs and the appropriate use of cell-free DNA tests as screening and not diagnostic tests.
- ACMGG specifically recommends against testing for aneuploidies (missing or extra chromosomes) other than those involving chromosomes related to Down syndrome (21), Edwards syndrome (18) and Patau syndrome (13).
- ACOG does not recommend the use of NIPTs to detect microdeletions.
- Test Results. In January 1, 2022, the New York Times (NYT) published an article entitled “When They Warn of Rare Disorders, These Prenatal Tests Are Usually Wrong.” According to the article, an examination by the NYT reveals that the predictions made by these tests are “usually wrong” and that according to NYT’s analysis the positive tests are incorrect about 85% of the time (for the five most common microdeletion tests performed).
The FDA safety communication discussed in f) above also points out that published studies strongly support the importance of performing confirmatory diagnostic testing to determine whether or not the fetus truly has a chromosomal abnormality following a positive screening test result. The scientific literature related to the use of NIPTs from laboratories, including 25 peer-reviewed publications covering 13 studies evaluating more than 10,000 individuals undergoing NIPTs, indicates that NIPTs evaluated generally perform well for ruling out disorders caused by chromosomal abnormalities. The scientific literature generally report high negative predictive values, greater than 99.9% when calculated which means that the fetus is very likely not to have a chromosomal abnormality if the test returns a negative result.
However, the literature confirms that the reliability of positive screening results is limited, particularly for microdeletions. Reliability of positive screening results in these studies was best for Down syndrome, with a positive predictive value of about 90%, meaning that one in 10 positive results are not confirmed as Down syndrome. However, reliability of positive screening results was far lower for microdeletions, with the positive predictive value ranging from about 2% to 30%, depending on the condition. For example, Di George syndrome, which is caused by a microdeletion on chromosome 22, showed a positive predictive value of about 30%. This means that, out of 10 patients receiving a positive result for Di George syndrome on a screening test, it is not confirmed in seven of those patients when diagnostic testing is performed with Corionic villous sampling or amniocentesis.
A 2022 article in the Journal of Clinical Medicine, entitled “Validity and Utility of Non-Invasive Prenatal Testing for Copy Number Variations and Microdeletions: A Systematic Review (systematic review),” the authors reviewed 32 study reports to evaluate the accuracy and reliability of NIPTs for copy number variants (CNVs or chromosomal aberrations) and microdeletions. The study concluded that “considering the limited follow-up and validation data available at this time, NIPT for microdeletions and CNVs should be used with caution and screen-positive results confirmed by invasive testing. Any developments regarding new technologies should undergo robust evaluation in terms of validity and clinical utility. The commercial implementation of NIPT should be subordinate to the public health sector. Standards for the inclusion of cfDNA-based screening methods into national health systems should be established by major organizations in the field of prenatal diagnostics.” - Laboratory Claims/Procedures in California. AB 80 (Committee on Budget), Chapter 12, Statutes of 2020, establishes the Health Care Payments Data Program (HPD) within the Department of Health Care Information and Access. According to the newly released HPD Snapshot, laboratory procedures rank second, third and fourth among the 25 most frequently reported medical procedures. As the snapshot reveals below, from 2018 to 2021, there were over 683 million laboratory procedures in California. Although the Snapshot does not yet include the total spending for these laboratory services, given the volume, one can conclude that spending for such services is quite high.
- Test Results. In January 1, 2022, the New York Times (NYT) published an article entitled “When They Warn of Rare Disorders, These Prenatal Tests Are Usually Wrong.” According to the article, an examination by the NYT reveals that the predictions made by these tests are “usually wrong” and that according to NYT’s analysis the positive tests are incorrect about 85% of the time (for the five most common microdeletion tests performed).
HPD Snapshot – Top Medical Procedures (2018-2021) | |||
Rank | Procedure Category | Type of Setting | Total Record Count |
1 | Office/outpatient services – Office visits | Provider | 334,761,088 |
2 | Laboratory – Chemistry and hematology | Independent Labs | 327,255,475 |
3 | Laboratory – Chemistry and hematology | Outpatient | 228,982,753 |
4 | Laboratory – Other | Independent Labs | 128,762,045 |
5 | Prophylactic vaccination and inoculations | Provider | 122,420,573 |
6 | Office/outpatient services – Office visits | Outpatient | 121,361,606 |
7 | Physical/occupational/speech therapy - exercises | Provider | 113,480,112 |
8 | Medications (injections, infusions, other forms) | Outpatient | 105,402,248 |
9 | Laboratory – Chemistry and hematology | Provider | 94,680,964 |
10 | Microscopic examination (i.e., lab, technology) | Independent Labs | 90,404,727 |
11 | Alcohol and drug management, treatment, and rehab | Provider | 83,603,005 |
12 | Psychological and psychiatric evaluation, therapy | Provider | 73,863,376 |
13 | Hospital inpatient services | Provider | 71,232,750 |
14 | Ophthalmologic/otology diagnosis and treatment | Provider | 68,878,781 |
15 | Transportation – patient, provider, equipment | Ambulance | 63,248,083 |
16 | CPT codes not classified (F codes) | Provider | 57,541,286 |
17 | DME and supplies | Provider | 56,011,167 |
18 | Laboratory – Other | Outpatient | 54,791,266 |
19 | Radiology – Diagnostic (other) | Provider | 52,087,215 |
20 | Non-hospital-based care (home health, hospice) | Home Health | 45,059,101 |
21 | Medications (injections, infusions, other forms) | Provider | 41,991,043 |
22 | Office/outpatient services – Preventive visits | Provider | 39,746,991 |
23 | Emergency department services | Provider | 38,783,729 |
24 | Microscopic examination (i.e., lab, technology) | Outpatient | 38,016,202 |
25 | Laboratory – Other | Provider | 35,753,925 |
- SUPPORT. The California Black Health Network (CBHN), in support of this bill that seeks to protect physician and patient choice within DPH’s PNS program. CBHN explains DPH recently proposed changes to the PNS program for pregnant individuals to receive testing for trisomy 13, 18, and 21, but sought to explicitly ban labs from offering screening outside of the PNS program. These changes would restrict patient and physician access to a clinical laboratory of their choice for important screening; would result in a substandard level of care for many Californians; and, would lead to disparities where patients with means and opportunity to purchase screening for additional conditions beyond trisomy 13, 18, and 21 will receive them, whereas patients who cannot afford them (primarily patients of color) will not. CBHN concludes that pregnant individuals and their doctors should be able to choose which tests are clinically appropriate and not DPH.
ACOG, also in support, states that restricting governmental interference with medical decisions and the patient and physician relationship is fundamental to the practice of medicine. Shared decisionmaking involves a discussion of the benefits and risks of all available testing and treatment options, in the context of a patient’s values and priorities. According to ACOG, the physicians ordering the screening and testing should – along with the patient – decide which screening or test is appropriate for the individual. Restrictions or limitations on what tests may be performed and who may perform the tests interfere with this vital patient-physician relationship and such decisions should not be regulated. - PREVIOUS LEGISLATION. SB 771 (Becker) of 2022 was substantially similar to this bill and would have prohibited DPH, by way of a rule, regulation, contract, or any other manner, from prohibiting a laboratory that has both a CLIA certificate of accreditation and a current state clinical or public health laboratory license from offering NIPT, or otherwise limit the number of tests that the laboratory may provide, including, but not limited to, testing for autosomal trisomies (trisomies 21, 18, and 13) and fetal sex, to a pregnant person who has an order from a prenatal care provider, as specified. SB 771 was held in the Assembly Appropriations Committee suspense file.
- AUTHOR’S AMENDMENTS. The author is proposing to amend this bill to delete “microdeletions.” It should be noted that this deletion does not preclude a laboratory from offering testing for microdeletions if ordered by a prenatal care provider.
- POLICY COMMENTS.
- Lack of Standard of Care for Unlimited Lab Tests. As drafted, this bill prohibits DPH from limiting the types of NIPTs that can be offered by a laboratory if the NIPT is ordered by a prenatal provider. This bill is a departure from existing law which requires DPH to expand prenatal screening to include all tests that meet or exceed the current standard of care as recommended by nationally recognized medical or genetic organizations. Thus, the expansion of NIPTs contemplated in this bill is contrary to this public policy and may not be in the best interest of pregnant people. For example, this bill (even with author’s amendments to delete reference to microdeletion) would allow for testing of microdeletions. As the FDA safety communication indicated above “ACOG does not recommend the use of NIPTs to detect microdeletions.”
The FDA’s safety communication also warns patients and health care providers about the risks of false results on some NIPTs adds to the concern that NIPT testing without guardrails may not be in the best interest of consumers. Thus, the Committee should consider whether allowing all commercial NIPT testing that does not meet the standard of care as recommended by medical or genetic organizations benefit pregnant people. - Patient safety and follow-up. As noted by DPH above, prenatal care providers who order prenatal screening outside of the PNS program will need to arrange for follow-up counseling and diagnostic testing for their patients outside of the state program if follow-up is necessary. It should be noted that there are no provisions in this bill that would require or inform pregnant individuals of the potential need for additional diagnostic services or follow-up care for those who opt out of the PNS program.
- Costs. As noted by DPH when the PNS program changes were being considered by the Legislature, DPH projected that reduced costs were anticipated for Medi-Cal, private insurers and pregnant people who pay out of pocket for their health care by covering cfDNA for all pregnant individuals. For example, DPH estimated that Medi-Cal would likely incur annual General Fund savings ranging from low to high hundreds of thousands compared to its current prenatal screening costs. DPH will charge a fee of $232 for cfDNA (there is a separate fee of $85 for neural tube defects screening). According to the NYT article, NIPTs can average from $695 for the basic test to $1,349 for the expanded panel. By expanding the types of NIPTs, this bill would increase the overall costs of healthcare both for public and private payors.
- Lack of Standard of Care for Unlimited Lab Tests. As drafted, this bill prohibits DPH from limiting the types of NIPTs that can be offered by a laboratory if the NIPT is ordered by a prenatal provider. This bill is a departure from existing law which requires DPH to expand prenatal screening to include all tests that meet or exceed the current standard of care as recommended by nationally recognized medical or genetic organizations. Thus, the expansion of NIPTs contemplated in this bill is contrary to this public policy and may not be in the best interest of pregnant people. For example, this bill (even with author’s amendments to delete reference to microdeletion) would allow for testing of microdeletions. As the FDA safety communication indicated above “ACOG does not recommend the use of NIPTs to detect microdeletions.”
REGISTERED SUPPORT / OPPOSITION:
Support
American College of Obstetricians and Gynecologists District IX
BillionToOne,
California Academy of Family Physicians
California Black Health Network
California Clinical Laboratory Association
California Life Sciences
California Nurse Midwives Association (CNMA)
Illumina, INC.
Natera, INC.
Opposition
None on file.
Analysis Prepared by: Rosielyn Pulmano / HEALTH / (916) 319-2097
SENATE RULES COMMITTEE Office of Senate Floor Analyses (916) 651-1520 Fax: (916) 327-4478 | SB 570 |
THIRD READING
Bill No: SB 570
Author: Becker (D), et al.
Amended: 4/10/23
Vote: 21
SENATE HEALTH COMMITTEE: 12-0, 3/29/23
AYES: Eggman, Nguyen, Glazer, Gonzalez, Grove, Hurtado, Limón, Menjivar, Roth, Rubio, Wahab, Wiener
SENATE APPROPRIATIONS COMMITTEE: 7-0, 5/18/23
AYES: Portantino, Jones, Ashby, Bradford, Seyarto, Wahab, Wiener
SUBJECT: Prenatal screening program
SOURCE: Author
DIGEST:
This bill prohibits the California Department of Public Health from prohibiting specified laboratories from offering all noninvasive prenatal tests, as ordered by a prenatal care provider, or otherwise limit the number of tests that the laboratory may provide to a pregnant person who has an order from a prenatal care provider.
ANALYSIS:
Existing law:
- Requires the California Department of Public Health (CDPH) to administer a statewide program for the prenatal testing for genetic disorders and birth defects, including, but not limited to, ultrasound, amniocentesis, chorionic villus sampling, and blood testing for genetic disorders and birth defects. [HSC §125050]
- Requires CDPH to establish criteria for eligibility for the prenatal testing program, and requires eligibility include a definition of conditions and circumstances that result in a high risk of a detectable genetic disorder or birth defect. Requires CDPH to expand prenatal screening to include all tests that meet or exceed the current standard of care as recommended by nationally recognized medical or genetic organizations. [HSC §125055]
- Requires the participation by any individual in the prenatal testing program to be voluntary and not be a prerequisite to eligibility for, or receipt of, any other service or assistance from, or participation in, any other program. [HSC §125060]
This bill prohibits CDPH, by way of rule, regulation, contract, or any other manner, from prohibiting a laboratory that has both a current Clinical Laboratory Improvement Amendments certificate of accreditation and a current state clinical or public health laboratory license from offering all noninvasive prenatal tests, as ordered by a prenatal care provider, or otherwise limit the number of tests that the laboratory may provide, including, but not limited to, testing for autosomal trisomies, microdeletions, and fetal sex, to a pregnant person who has an order from a prenatal care provider.
Comments
- Author’s statement. According to the author, this bill seeks to restore a pregnant individual’s decision to utilize all available prenatal services to make informed decisions about their and their newborn’s healthcare. Pregnant individuals and their physicians commonly seek screening for a variety of sex chromosomes anomalies that can have significant impacts on the pregnancy and the newborn. Known as Non-Invasive Prenatal Testing (NIPT), this prenatal cell-free DNA (cfDNA) screening is the primary prenatal screening for these anomalies. In late 2022, however, the CDPH implemented major changes to the Prenatal Screening (PNS) Program, which impede access to certain services that pregnant individuals previously enjoyed. These changes limit the types of genetic screening pregnant individuals are able to receive through the PNS Program. This bill will once again allow pregnant individuals to access specific types of genetic screening – regardless of their PNS enrollment status – as recommended by their prenatal care provider.
- California’s PNS Program. NIPT is a method of determining the risk that a fetus will be born with certain genetic abnormalities by analyzing a pregnant person’s blood. NIPTs are screening tests, not diagnostic tests, and predict a level of risk of the fetus having certain genetic abnormalities (diagnostic tests are used to confirm or rule out a suspected genetic abnormality). According to the CDPH website, the PNS Program is offered statewide by prenatal care providers to all pregnant individuals. Those who choose to participate provide blood samples for two types of prenatal screening (cfDNA screening and maternal serum alpha-fetoprotein (MSAFP) screening). These tests screen for:
- Down syndrome (trisomy 21): people with Down syndrome usually have an IQ in the mildly-to-moderately low range and are slower to speak than other children;
- Trisomy 13 (Patau syndrome) and trisomy 18 (Edwards syndrome): these syndromes can cause distinctive physical features, structural birth defects, and developmental disabilities. Most babies with trisomy 13 and 18 are lost through miscarriage; and,
- Neural tube defects (NTDs like spina bifida and anencephaly): when there is an opening in the spine, it is called spina bifida, which often causes paralysis of the baby's legs and may also cause loss of bowel and bladder control. Anencephaly occurs when most of the brain does not develop. This defect causes the death of the baby or newborn.
Individuals with a fetus found to have an increased chance of certain birth defects are offered genetic counseling and other follow-up services through state-contracted Prenatal Diagnosis Centers. The PNS Program makes comprehensive prenatal screening available for $232 (trisomies 13, 18 and 21) and $85 (NTDs). Genetic counseling and follow-up diagnostic testing and other services for individuals found to be at high risk are included in these fees. Medi-Cal or private health insurance covers the program fees and with no cost sharing for patients (with only a few exceptions for self-insured employers and out-of-state health plans).
- Changes to the PNS Program. In 2020, the American College of Obstetricians and Gynecologists (ACOG) released updated guidance indicating that cfDNA screening for trisomies 21, 18 and 13 is the standard of care, and CDPH was statutorily required to implement the new standard of care (see #2 in existing law above). As part of the state’s 2021-22 Budget, the Administration proposed and the Legislature approved a transition to cfDNA screening for trisomies 21, 18 and 13 in the PNS Program. According to CDPH, before it proposed making changes to the PNS Program, it conducted stakeholder meetings beginning in 2019. Representatives from laboratories, ACOG, and others from the genetic counseling, prenatal, and bioethics community were invited and participated in a discussion about the PNS Program redesign. CDPH indicates that it continued to consult with stakeholders and invite input since the 2019 meeting in the form of webinars for PNS providers, newsletters, and announcements. In 2019 and 2021, DPH surveyed cfDNA labs for input to the PNS program and CDPH/PNS Program staff had a series of meetings with interested cfDNA labs since then. According to CDPH, it also engaged in late 2021 and 2022 with leadership from ACOG District IX, which covers California, as well as national ACOG officials. Based upon these discussions, as well as evolution or clarification of guidance documents, CDPH is now proposing to add screening for sex chromosome aneuploids to its cfDNA platform and is in early stages of discussion for implementation.
As part of the program redesign, CDPH issued emergency regulations, which were adopted on September 9, 2022. A provision contained in these regulations allow only labs contracted with CDPH to perform prenatal screening for NTDs or perform cfDNA screening for trisomies 13, 18 and 21. CDPH indicates that they currently have contracts with Quest Diagnostics, Naterra, Perkin Elmer, and Kaiser Southern California for testing through the PNS Program. Several cfDNA laboratories subsequently sued to challenge the regulatory authority. A preliminary injunction against CDPH was issued and took effect on November 2, 2022. This ruling meant that labs that have not contracted with the PNS Program are currently able to screen for trisomy 13, trisomy 18, trisomy 21 and NTDs outside of the PNS Program.
- FDA warning. Given the increased use of NIPTs and recent media reports, on April 19, 2022 the U.S. Food and Drug Administration (FDA) warned the public of the risk of false results, inappropriate use, and inappropriate interpretation of results with these screening tests. The FDA stated that “patients and health care providers should be aware of the risks and limitations of using these genetic prenatal screening tests and that they should not be used alone to diagnose chromosomal (genetic) abnormalities. However, the FDA is aware of reports that patients and health care providers have made critical health care decisions based on results from these screening tests without additional confirmatory testing. Pregnant people have ended pregnancies based on the results of genetic prenatal screening alone, without understanding the limitations of the screening tests and that the fetus may not have the genetic abnormality identified by the screening test.” The FDA recommends that patients and health care providers discuss the benefits and risks of all prenatal genetic testing with a genetic counselor or other health care provider before considering such testing or making any decisions about their pregnancy.
Related/Prior Legislation
SB 771 (Becker of 2022) would have prohibited CDPH from preventing a clinical laboratory, as specified, from offering NIPT to a pregnant person who has opted out of the PNS Program or chosen to have testing in addition to the genetic tests offered as part of the PNS Program. SB 771 was held on the Assembly Appropriations Committee suspense file.
FISCAL EFFECT: Appropriation: No Fiscal Com.: Yes Local: No
According to the Senate Appropriations Committee:
- Unknown cost pressures in the Medi-Cal program (General Fund and federal funds) to the extent that pregnant individuals enrolled in Medi-Cal would opt for prenatal testing outside of CDPH’s PNS Program or choose to have tests in addition to the genetic tests offered as part of the PNS Program. Currently, Medi-Cal payment rates to laboratories for prenatal testing are generally higher than PNS payment rates. If a Medi-Cal patient receives prenatal testing through the PNS Program, Medi-Cal will cover the cost at the lower PNS rate.
- CDPH anticipates decreased PNS Program expenditures and revenues as pregnant individuals seek prenatal testing outside of the PNS Program. However, CDPH estimates that between $4.2 million to $17.5 million (Genetic Disease Testing Fund) in revenue loss would need to be offset by an increase in the fees charged for the PNS Program, to cover fixed operational program costs.
SUPPORT: (Verified 5/17/23)
American College of Obstetricians and Gynecologists, District IX
BillionToOne
California Clinical Laboratory Association
California Life Sciences
California Nurse Midwives Association
Illumina
Myriad Genetics Inc.
Natera
Planned Parenthood Affiliates of California
OPPOSITION: (Verified 5/17/23)
None received
ARGUMENTS IN SUPPORT: ACOG, District IX writes that shared decision making involves a discussion of the benefits and risks of all available testing and treatment options, in the context of a patient’s values and priorities. The physicians ordering the screening and testing should – along with the patient – decide which screening or test is appropriate for the individual. Restrictions or limitations on what tests may be performed and who may perform the tests interfere with this vital patient-physician relationship and such decisions should not be regulated. California Life Sciences states that this bill would enable accredited testing laboratories to offer noninvasive prenatal tests to pregnant women in addition to or instead of the tests offered through the PNS Program, in turn providing an opportunity for patients to choose their own care when it comes to prenatal screening. The California Clinical Laboratories Association writes that its biggest concern with the changes made to the PNS Program is that they will limit a woman’s choice for receiving crucial laboratory testing relating to the health of her pregnancy. Currently, pregnant women in California have multiple options for prenatal screening. They can choose to participate in the state prenatal screening program, or they can access testing at multiple laboratories across the state. It would be a drastic step backwards to force all women into the state program or deny them access to this testing. If a laboratory is properly licensed by the federal and state government, they should be allowed to continue offering prenatal screening. Planned Parenthood Affiliates of California writes that while the transition to NIPT is welcomed, CDPH’s program presents significant problems to physicians and their patients, labs and others in the genetic testing industry, and this bill addresses these problems by giving Californians a choice and access in their prenatal screening, rather than forcing them to enroll in the PNS Program to receive screenings.
Prepared by: Melanie Moreno / HEALTH / (916) 651-4111
5/20/23 13:00:26
**** END ****
SENATE COMMITTEE ON
Senator Anthony Portantino, Chair
2023 - 2024 Regular Session
SB 570 (Becker) - Prenatal screening program
Version: | Policy Vote: |
Urgency: | Mandate: |
Hearing Date: April 17, 2023 | Consultant: |
Bill Summary:
SB 570 would prevent the California Department of Public Health (CDPH) from prohibiting a laboratory, as specified, from offering all noninvasive prenatal tests, as ordered by a prenatal care provider, or otherwise limit the number of tests that the laboratory may provide to a pregnant person who has an order from a prenatal care provider.
Fiscal Impact:
- Unknown cost pressures in the Medi-Cal program (General Fund and federal funds) to the extent that pregnant individuals enrolled in Medi-Cal would opt for prenatal testing outside of CDPH’s Prenatal Screening (PNS) program or choose to have tests in addition to the genetic tests offered as part of the PNS program. Currently, Medi-Cal payment rates to laboratories for prenatal testing are generally higher than PNS payment rates. If a Medi-Cal patient receives prenatal testing through the PNS program, Medi-Cal will cover the cost at the lower PNS rate.
- CDPH anticipates decreased PNS program expenditures and revenues as pregnant individuals seek prenatal testing outside of the PNS program. However, CDPH estimates that between $4.2 million to $17.5 million (Genetic Disease Testing Fund) in revenue loss would need to be offset by an increase in the fees charged for the PNS program, to cover fixed operational program costs.
Background:
CDPH administers the PNS program, a statewide program for the prenatal testing for genetic disorders and birth defects, including, but not limited to, ultrasound, amniocentesis, chorionic villus sampling, and blood testing for genetic disorders and birth defects. CDPH establishes criteria for eligibility for the prenatal testing program, including a definition of conditions and circumstances that result in a high risk of a detectable genetic disorder or birth defect. Current law requires CDPH to expand prenatal screening to include all tests that meet or exceed the current standard of care as recommended by nationally recognized medical or genetic organizations. Participation by any individual in the prenatal testing program is voluntary.
As part of the PNS program, Non-Invasive Prenatal Testing (NIPT) is a method of determining the risk that a fetus will be born with certain genetic abnormalities by analyzing a pregnant person’s blood. NIPTs are screening tests, not diagnostic tests, and predict a level of risk of the fetus having certain genetic abnormalities (diagnostic tests are used to confirm or rule out a suspected genetic abnormality). According to the CDPH website, the PNS program is offered statewide by prenatal care providers to all pregnant individuals. Those who choose to participate provide blood samples for two types of prenatal screening (cfDNA screening and maternal serum alpha-fetoprotein (MSAFP) screening). These tests screen for:
a) Down syndrome (trisomy 21): people with Down syndrome usually have an IQ in the mildly-to-moderately low range and are slower to speak than other children;
b) Trisomy 13 (Patau syndrome) and trisomy 18 (Edwards syndrome): these syndromes can cause distinctive physical features, structural birth defects, and developmental disabilities. Most babies with trisomy 13 and 18 are lost through miscarriage; and,
c) Neural tube defects (NTDs like spina bifida and anencephaly): when there is an opening in the spine, it is called spina bifida, which often causes paralysis of the baby's legs and may also cause loss of bowel and bladder control. Anencephaly occurs when most of the brain does not develop. This defect causes the death of the baby or newborn.
Individuals with a fetus found to have an increased chance of certain birth defects are offered genetic counseling and other follow-up services through state-contracted Prenatal Diagnosis Centers. The PNS program makes comprehensive prenatal screening available for $232 (trisomies 13, 18 and 21) and $85 (NTDs). Genetic counseling and follow-up diagnostic testing and other services for individuals found to be at high risk are included in these fees. Medi-Cal or private health insurance covers the program fees and with no cost sharing for patients (with only a few exceptions for self-insured employers and out-of-state health plans).
As part of a program redesign, CDPH issued emergency regulations in 2022 that contained a provision to allow only labs contracted with CDPH to perform prenatal screening for NTDs or perform cfDNA screening for trisomies 13, 18 and 21. Several cfDNA laboratories subsequently sued to challenge the regulatory authority. A preliminary injunction against CDPH was issued and took effect on November 2, 2022. This ruling meant that labs that have not contracted with the PNS program are currently able to screen for trisomy 13, trisomy 18, trisomy 21 and NTDs outside of the PNS program.
Proposed Law:
SB 570 would prevent the CDPH from prohibiting a laboratory that has both a current Clinical Laboratory Improvement Amendments certificate of accreditation and a current state clinical or public health laboratory license from offering all noninvasive prenatal tests, as ordered by a prenatal care provider, or otherwise limit the number of tests that the laboratory may provide, including, but not limited to, testing for autosomal trisomies (trisomies 21, 18, and 13), microdeletions, and fetal sex, to a pregnant person who has an order from a prenatal care provider.
Related Legislation:
SB 771 (Becker, 2022), substantially amended in the Assembly, would have prohibited CDPH from preventing a clinical laboratory, as specified, from offering NIPT to a pregnant person who has opted out of the PNS program or chosen to have testing in addition to the genetic tests offered as part of the PNS program. SB 771 was held on the suspense file in the Assembly Appropriations Committee.
-- END --
SENATE COMMITTEE ON HEALTH
Senator Dr. Susan Talamantes Eggman, Chair
BILL NO: SB 570
AUTHOR: | Becker | ||
VERSION: | February 15, 2023 | ||
HEARING DATE: | March 29, 2023 | ||
CONSULTANT: | Melanie Moreno | ||
SUBJECT: Prenatal screening program
SUMMARY:
Prohibits the California Department of Public Health from interfering with a pregnant individual’s ability to secure genetic screening testing as recommended or ordered by the pregnant individual’s prenatal care provider.
Existing law:
- Requires the California Department of Public Health (CDPH) to administer a statewide program for the prenatal testing for genetic disorders and birth defects, including, but not limited to, ultrasound, amniocentesis, chorionic villus sampling, and blood testing for genetic disorders and birth defects. [HSC §125050]
- Requires CDPH to establish criteria for eligibility for the prenatal testing program, and requires eligibility include a definition of conditions and circumstances that result in a high risk of a detectable genetic disorder or birth defect. Requires CDPH to expand prenatal screening to include all tests that meet or exceed the current standard of care as recommended by nationally recognized medical or genetic organizations. [HSC §125055]
- Requires the participation by any individual in the prenatal testing program to be voluntary and not be a prerequisite to eligibility for, or receipt of, any other service or assistance from, or participation in, any other program. [HSC §125060]
This bill: Prohibits CDPH, by way of rule, regulation, contract, or any other manner, from interfering with a pregnant individual’s ability to secure genetic screening testing as recommended or ordered by the pregnant individual’s prenatal care provider.
FISCAL EFFECT:
This bill has not been analyzed by a fiscal committee.
COMMENTS:
- Author’s statement. According to the author, this bill seeks to restore a pregnant individual’s decision to utilize all available prenatal services to make informed decisions about their and their newborn’s healthcare. Pregnant individuals and their physicians commonly seek screening for a variety of sex chromosomes anomalies that can have significant impacts on the pregnancy and the newborn. Known as Non-Invasive Prenatal Testing (NIPT), this prenatal cell-free DNA (cfDNA) screening is the primary prenatal screening for these anomalies. In late 2022, however, the CDPH implemented major changes to the Prenatal Screening (PNS) Program, which impede access to certain services that pregnant individuals previously enjoyed. These changes limit the types of genetic screening pregnant individuals are able to receive through the PNS Program. This bill will once again allow pregnant individuals to access specific types of genetic screening – regardless of their PNS enrollment status – as recommended by their prenatal care provider.
- California’s PNS Program. NIPT is a method of determining the risk that a fetus will be born with certain genetic abnormalities by analyzing a pregnant person’s blood. NIPTs are screening tests, not diagnostic tests, and predict a level of risk of the fetus having certain genetic abnormalities (diagnostic tests are used to confirm or rule out a suspected genetic abnormality). According to the CDPH website, the PNS Program is offered statewide by prenatal care providers to all pregnant individuals. Those who choose to participate provide blood samples for two types of prenatal screening (cfDNA screening and maternal serum alpha-fetoprotein (MSAFP) screening). These tests screen for:
- Down syndrome (trisomy 21): people with Down syndrome usually have an IQ in the mildly-to-moderately low range and are slower to speak than other children;
- Trisomy 13 (Patau syndrome) and trisomy 18 (Edwards syndrome): these syndromes can cause distinctive physical features, structural birth defects, and developmental disabilities. Most babies with trisomy 13 and 18 are lost through miscarriage; and,
- Neural tube defects (NTDs like spina bifida and anencephaly): when there is an opening in the spine, it is called spina bifida, which often causes paralysis of the baby's legs and may also cause loss of bowel and bladder control. Anencephaly occurs when most of the brain does not develop. This defect causes the death of the baby or newborn.
Individuals with a fetus found to have an increased chance of certain birth defects are offered genetic counseling and other follow-up services through state-contracted Prenatal Diagnosis Centers. The PNS Program makes comprehensive prenatal screening available for $232 (trisomies 13, 18 and 21) and $85 (NTDs). Genetic counseling and follow-up diagnostic testing and other services for individuals found to be at high risk are included in these fees. Medi-Cal or private health insurance covers the program fees and with no cost sharing for patients (with only a few exceptions for self-insured employers and out-of-state health plans).
- Changes to the PNS Program. In 2020, the American College of Obstetricians and Gynecologists (ACOG) released updated guidance indicating that cfDNA screening for trisomies 21, 18 and 13 is the standard of care, and CDPH was statutorily required to implement the new standard of care (see #2 in existing law above). As part of the state’s 2021-22 Budget, the Administration proposed and the Legislature approved a transition to cfDNA screening for trisomies 21, 18 and 13 in the PNS Program. According to CDPH, before it proposed making changes to the PNS Program, it conducted stakeholder meetings beginning in 2019. Representatives from laboratories, ACOG, and others from the genetic counseling, prenatal, and bioethics community were invited and participated in a discussion about the PNS Program redesign. CDPH indicates that it continued to consult with stakeholders and invite input since the 2019 meeting in the form of webinars for PNS providers, newsletters, and announcements. In 2019 and 2021, DPH surveyed cfDNA labs for input to the PNS program and CDPH/PNS Program staff had a series of meetings with interested cfDNA labs since then. According to CDPH, it also engaged in late 2021 and 2022 with leadership from ACOG District IX, which covers California, as well as national ACOG officials. Based upon these discussions, as well as evolution or clarification of guidance documents, CDPH is now proposing to add screening for sex chromosome aneuploids to its cfDNA platform and is in early stages of discussion for implementation.
As part of the program redesign, CDPH issued emergency regulations, which were adopted on September 9, 2022. A provision contained in these regulations allow only labs contracted with CDPH to perform prenatal screening for NTDs or perform cfDNA screening for trisomies 13, 18 and 21. CDPH indicates that they currently have contracts with Quest Diagnostics, Naterra, Perkin Elmer, and Kaiser Southern California for testing through the PNS Program. Several cfDNA laboratories subsequently sued to challenge the regulatory authority. A preliminary injunction against CDPH was issued and took effect on November 2, 2022. This ruling meant that labs that have not contracted with the PNS Program are currently able to screen for trisomy 13, trisomy 18, trisomy 21 and NTDs outside of the PNS Program.
- FDA warning. Given the increased use of NIPTs and recent media reports, on April 19, 2022 the U.S. Food and Drug Administration (FDA) warned the public of the risk of false results, inappropriate use, and inappropriate interpretation of results with these screening tests. The FDA stated that “patients and health care providers should be aware of the risks and limitations of using these genetic prenatal screening tests and that they should not be used alone to diagnose chromosomal (genetic) abnormalities. However, the FDA is aware of reports that patients and health care providers have made critical health care decisions based on results from these screening tests without additional confirmatory testing. Pregnant people have ended pregnancies based on the results of genetic prenatal screening alone, without understanding the limitations of the screening tests and that the fetus may not have the genetic abnormality identified by the screening test.” The FDA recommends that patients and health care providers discuss the benefits and risks of all prenatal genetic testing with a genetic counselor or other health care provider before considering such testing or making any decisions about their pregnancy.
- Prior legislation. SB 771 (Becker of 2022) would have prohibited CDPH from preventing a clinical laboratory, as specified, from offering NIPT to a pregnant person who has opted out of the PNS Program or chosen to have testing in addition to the genetic tests offered as part of the PNS Program. SB 771 was held on the Assembly Appropriations Committee suspense file.
- Support. ACOG, District IX writes that shared decision making involves a discussion of the benefits and risks of all available testing and treatment options, in the context of a patient’s values and priorities. The physicians ordering the screening and testing should – along with the patient – decide which screening or test is appropriate for the individual. Restrictions or limitations on what tests may be performed and who may perform the tests interfere with this vital patient-physician relationship and such decisions should not be regulated. California Life Sciences states that this bill would enable accredited testing laboratories to offer noninvasive prenatal tests to pregnant women in addition to or instead of the tests offered through the PNS Program, in turn providing an opportunity for patients to choose their own care when it comes to prenatal screening. The California Clinical Laboratories Association writes that its biggest concern with the changes made to the PNS Program is that they will limit a woman’s choice for receiving crucial laboratory testing relating to the health of her pregnancy. Currently, pregnant women in California have multiple options for prenatal screening. They can choose to participate in the state prenatal screening program, or they can access testing at multiple laboratories across the state. It would be a drastic step backwards to force all women into the state program or deny them access to this testing. If a laboratory is properly licensed by the federal and state government, they should be allowed to continue offering prenatal screening. Planned Parenthood Affiliates of California writes that while the transition to NIPT is welcomed, CDPH’s program presents significant problems to physicians and their patients, labs and others in the genetic testing industry, and this bill addresses these problems by giving Californians a choice and access in their prenatal screening, rather than forcing them to enroll in the PNS Program to receive screenings.
- Policy comment. This bill has the same intent as last year’s SB 771, which is to require that all labs be permitted to provide NIPT. However, the language in this bill prohibiting CDPH from “interfering” with the ability to secure genetic screening is not as direct as SB 771. To ensure that this bill has the intended effect, the author may wish to consider more specific language, such as prohibiting CDPH from requiring laboratories to be contracted under the PNS Program as a condition of being able to perform prenatal screenings.
SUPPORT AND OPPOSITION:
Support: American College of Obstetricians and Gynecologists, District IX
BillionToOne
California Clinical Laboratory Association
California Life Sciences
Illumina
Myriad Genetics Inc.
Natera
Planned Parenthood Affiliates of California
Oppose: None received.
-- END --
Discussed in Hearing
Assembly Standing Committee on Health
Senate Standing Committee on Health
Bill Author
Bill Co-Author(s):